Methods and compositions of derivatives of probucol for the treatment of diabetes

Abstract

This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a monoester of probucol, particularly the monosuccinic acid ester, or a pharmaceutically acceptable salt or derivative thereof.

1 . A method for the treatment or prophylaxis of diabetes, a pre-diabetes condition or a diabetes related disorder in a host, comprising administering a compound of formula (B): 
       
         
           
           
               
               
           
         
         wherein 
         R a , R b , R c , and R d  are independently hydrogen, straight chained, branched (for example, tert-butyl), or cyclic alkyl which may be substituted, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl, aralkyl or substituted aralkyl; substituents on the R a , R b , R c  and R d  groups are selected from the group consisting of hydrogen, halogen, alkyl, nitro, amino, haloalkyl, alkylamino, dialkylamino, acyl, and acyloxy; 
         Z is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, aralkyl, alkaryl, heteroaryl, heteroaralkyl, a carbohydrate group, —(CH 2 ) n —R e , —C(O)—R g , and —C(O)—(CH 2 ) n —R h , wherein when each of R a , R b , R c , and R d  are t-butyl, Z cannot be hydrogen, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; 
         R e  is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, substituted alkoxyalkyl, NH 2 , NHR, NR 2 , mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyloxy, substituted acyloxy, COOH, COOR, —CH(OH)R k , hydroxy, C(O)NH 2 , C(O)NHR, C(O)NR 2 , and epoxy; 
         R g  is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, substituted alkoxyalkyl, NH 2 , NHR, NR 2 , mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; 
         R h  is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, substituted alkoxyalkyl, NH 2 , NHR, NR 2 , mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyloxy, substituted acyloxy, COOH, COOR, —CH(OH)R k , hydroxy, O-phosphate, C(O)NH 2 , C(O)NHR, C(O)NR 2 , C(O)-heteroaryl, C(O)-(glycine), C(O)-(arginine), C(O)-(glutamic acid), and C(O)-(lysine); 
         R k  is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, substituted alkoxyalkyl, NH 2 , NHR, NR 2 , mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyloxy, substituted acyloxy, COOH, COOR, —CH(OH)R, hydroxy, C(O)NH 2 , C(O)NHR, and C(O)NR 2 ; 
         R is alkyl, alkenyl, alkynyl, aryl, alkyl-C(O)OH, alkyl-C(O)O-alkyl, alkyl-C(O)O-aryl, heteroaryl, wherein any of these groups are optionally substituted, or when attached to a nitrogen atom, two adjacent R groups may combine to form a ring of 5 to 7 members; and substitutents on the groups defined above in Formula B are selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxy, halo, nitro, amino, alkylamino, dialkylamino, carboxy, aryl, heteroaryl, COOR, CONH 2 , CONHR, CONR 2 , haloalkyl, alkoxyalkyl, mono- or polyhydroxyalkyl, CH 2 —OR, CH 2 —OH, OCOR, O-phosphate, SO 2 —NH 2 , SO 2 —NHR, SO 2 —NR 2 , sulfonic acid and phosphonic acid, any of which can be further substituted. 
       
     
     
         2 . The method of  claim 1 , wherein R a , R b , R c  and R d  are alkyl. 
     
     
         3 . The method of  claim 1  wherein Z is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, a carbohydrate group, —(CH 2 ) n —R e , —C(O)—R g , and —C(O)—(CH 2 ) n —R h , and pharmaceutically acceptable salts thereof. 
     
     
         4 . The method of  claim 1  wherein Z is selected from the group consisting of alkyl, substituted alkyl, —C(O)—R g , and —C(O)—(CH 2 ) n —R h , and pharmaceutically acceptable salts thereof. 
     
     
         5 . The method of  claim 1  wherein the host has been diagnosed with diabetes. 
     
     
         6 . The method of  claim 1  wherein the host is at risk of or diagnosed with diabetes is at risk of or diagnosed with type 2 diabetes or a pre-diabetes condition. 
     
     
         7 . The method of  claim 1  wherein the method improves insulin sensitivity in a host. 
     
     
         8 . A method for the treatment or prophylaxis of diabetes, a pre-diabetes condition or a diabetes related disorder in a host, comprising administering an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         wherein x is selected from 1, 2, 3 or 4; 
         or a pharmaceutically acceptable salt, ester, pharmaceutically acceptable derivative, or prodrug thereof. 
       
     
     
         9 . The method of  claim 8  wherein x is 2 or 3. 
     
     
         10 . The method of  claim 8  wherein the host has been diagnosed with diabetes. 
     
     
         11 . The method of  claim 8  wherein the host is at risk of or diagnosed with diabetes is at risk of or diagnosed with type 2 diabetes or a pre-diabetes condition. 
     
     
         12 . The method of  claim 8  wherein the method improves insulin sensitivity in a host. 
     
     
         13 . A method for the treatment or prophylaxis of diabetes, a pre-diabetes condition or a diabetes related disorder in a host, comprising administering an effective amount of a monosuccinic acid ester of probucol of the structure: 
       
         
           
           
               
               
           
         
         or a salt thereof. 
       
     
     
         14 . A method for the treatment or prophylaxis of diabetes, a pre-diabetes condition or a diabetes related disorder in a host, comprising administering a compound of Formula II: 
       
         
           
           
               
               
           
         
         wherein x is selected from 1, 2, 3 or 4; 
         or a pharmaceutically acceptable salt, ester, pharmaceutically acceptable derivative, or prodrug thereof. 
       
     
     
         15 . The method of  claim 14  wherein x is 1. 
     
     
         16 . The method of  claim 14  wherein the host has been diagnosed with diabetes. 
     
     
         17 . The method of  claim 14  wherein the host is at risk of or diagnosed with diabetes is at risk of or diagnosed with type 2 diabetes or a pre-diabetes condition. 
     
     
         18 . The method of  claim 14  wherein the method improves insulin sensitivity in a host. 
     
     
         19 . A method of glycemic control in a host in need thereof is provided, including administering an effective amount of a compound of Formula (B): 
       
         
           
           
               
               
           
         
         wherein 
         R a , R b , R c , and R d  are independently hydrogen, straight chained, branched (for example, tert-butyl), or cyclic alkyl which may be substituted, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl, aralkyl or substituted aralkyl; substituents on the R a , R b , R c  and R d  groups are selected from the group consisting of hydrogen, halogen, alkyl, nitro, amino, haloalkyl, alkylamino, dialkylamino, acyl, and acyloxy; 
         Z is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, aralkyl, alkaryl, heteroaryl, heteroaralkyl, a carbohydrate group, —(CH 2 ) n —R e , —C(O)—R g , and —C(O)—(CH 2 ) n —R h , wherein when each of R a , R b , R c , and R d  are t-butyl, Z cannot be hydrogen; 
         n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; 
         R e  is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, substituted alkoxyalkyl, NH 2 , NHR, NR 2 , mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyloxy, substituted acyloxy, COOH, COOR, —CH(OH)R k , hydroxy, C(O)NH 2 , C(O)NHR, C(O)NR 2 , and epoxy; 
         R g  is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, substituted alkoxyalkyl, NH 2 , NHR, NR 2 , mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; 
         R h  is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, substituted alkoxyalkyl, NH 2 , NHR, NR 2 , mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyloxy, substituted acyloxy, COOH, COOR, —CH(OH)R k , hydroxy, O-phosphate, C(O)NH 2 , C(O)NHR, C(O)NR 2 , C(O)-heteroaryl, C(O)-(glycine), C(O)-(arginine), C(O)-(glutamic acid), and C(O)-(lysine); 
         R k  is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, substituted alkoxyalkyl, NH 2 , NHR, NR 2 , mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyloxy, substituted acyloxy, COOH, COOR, —CH(OH)R, hydroxy, C(O)NH 2 , C(O)NHR, and C(O)NR 2 ; 
         R is alkyl, alkenyl, alkynyl, aryl, alkyl-C(O)OH, alkyl-C(O)O-alkyl, alkyl-C(O)O-aryl, heteroaryl, wherein any of these groups are optionally substituted, or when attached to a nitrogen atom, two adjacent R groups may combine to form a ring of 5 to 7 members; and substitutents on the groups defined above in Formula B are selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxy, halo, nitro, amino, alkylamino, dialkylamino, carboxy, aryl, heteroaryl, COOR, CONH 2 , CONHR, CONR 2 , haloalkyl, alkoxyalkyl, mono- or polyhydroxyalkyl, CH 2 —OR, CH 2 —OH, OCOR, O-phosphate, SO 2 —NH 2 , SO 2 —NHR, SO 2 —NR 2 , sulfonic acid and phosphonic acid, any of which can be further substituted. 
       
     
     
         20 . The method of  claim 19 , wherein R a , R b , R c  and R d  are alkyl. 
     
     
         21 . The method of  claim 19  wherein Z is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, a carbohydrate group, —(CH 2 ) n —R e , —C(O)—R g , and —C(O)—(CH 2 ) n —R h , and pharmaceutically acceptable salts thereof. 
     
     
         22 . The method of  claim 19  wherein Z is selected from the group consisting of alkyl, substituted alkyl, —C(O)—R g , and —C(O)—(CH 2 ) n —R h , and pharmaceutically acceptable salts thereof. 
     
     
         23 . A method of glycemic control in a host in need thereof is provided, including administering an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         wherein x is selected from 1, 2, 3 or 4; 
         or a pharmaceutically acceptable salt, ester, pharmaceutically acceptable derivative, or prodrug thereof. 
       
     
     
         24 . The method of  claim 23  wherein x is 2 or 3. 
     
     
         25 . A method of glycemic control in a host in need thereof is provided, including administering an effective amount of a compound of a monosuccinic acid ester of probucol of the structure: 
       
         
           
           
               
               
           
         
         or a salt thereof. 
       
     
     
         26 . A method of glycemic control in a host in need thereof is provided, including administering an effective amount of a compound of Formula II: 
       
         
           
           
               
               
           
         
         wherein x is selected from 1, 2, 3 or 4; 
         or a pharmaceutically acceptable salt, ester, pharmaceutically acceptable derivative, or prodrug thereof. 
       
     
     
         27 . The method of  claim 26  wherein x is 1.